SUDA Update On Discussions with Berlin Pharma
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Suspension from official quotation
- SUDA presents data on novel technology
- SUDA Enters Licensing Agreement For ZolpiMist in China
- Technology patent application
- Update on HC Berlin Pharma
Later from Arovella Therapeutics
- SUDA Announces Strong Revenue For Westcoast
- SUDA expands patent coverage for SUD-003 and SUD-004
- SUDA Enters Feasibility Agreement With Pfizer
- SUDA Extends Maturity of Convertible Notes
- SUDA Submits Application For ArTiMist
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics